New Arthritis Drugs Reduce Ulcer Risk -- At a Cost
Nov. 23, 1999 (Seattle) -- Two newly approved arthritis drugs are as
effective as traditional medicines but are less likely to cause ulcers,
according to a pair of studies in the Nov. 24 issue of the Journal of the
American Medical Association. But an accompanying editorial suggests that
for many people, the new drugs may not be worth the cost.
"These are good drugs, but they're not necessary for everyone," says
Walter Peterson, MD. Peterson is a researcher at the Dallas VA Medical Center,
a faculty member at the University of Texas Southwestern Medical Center at
Dallas, and one of the authors of the editorial. Peterson tells WebMD, "If
you are young and healthy, you're going to pay a lot more without getting much
He estimates that a typical arthritis patient would spend more than $70 a
month for one of the new drugs, compared with less than $10 a month for a
The studies look at the prescription drugs Celebrex (celecoxib) and Vioxx
(rofecoxib), both of which have reached the market in the past few months. The
drugs were designed to prevent pain and inflammation the same way products such
as ibuprofen or aspirin do. Unlike ibuprofen, aspirin, and other nonsteroidal
anti-inflammatory drugs (NSAIDs), Celebrex and Vioxx are designed so that they
do not cause changes in the lining of the stomach and intestine that can lead
The new studies confirm that the drugs are safe and effective. "They do
exactly what they are supposed to do," says Lee Simon, MD, the lead
researcher of one of the studies and a faculty member at Harvard Medical
School. He tells WebMD, "Every patient who is taking medication for
arthritis pain needs to know about these new drugs."
Simon led a team that studied Celebrex, which has become a best-selling
product in the U.S. The researchers found that for 1,149 people with rheumatoid
arthritis, the drug was as effective as a traditional NSAID at reducing pain
and inflammation. But examination of the patients' stomach and upper
gastrointestinal tract showed that less than 6% of people taking these newer
anti-inflammatory agents had ulcers, compared with 26% of people taking the
older NSAIDs. Most of the ulcers were so small, however, that patients were
unaware they had them.
The second study, led by a researcher from Birmingham, England, looked at
the risk of serious ulcers among people who took Vioxx. To increase accuracy,
researchers combined the results of eight studies that included a total of more
than 5,000 patients who took Vioxx for arthritis.
The researchers found that people taking Vioxx were about half as likely as
those taking a traditional NSAID to have ulcers that perforated the stomach
wall, which caused bleeding or pain.